SloveniaBora Pharmaceuticals completed the acquisition of MacroGenics' Rockville, Maryland manufacturing operations for $122.5 million, expanding its biologics manufacturing capacity in the U.S. The deal includes a 20,000-liter single-use bioreactor platform across two U.S. sites and one in Taiwan. This enhances Bora's ability to provide end-to-end biologics services, from development to commercial supply, with support for over 40 active programs and compliance with global regulatory standards. The integration of U.S.-based facilities aims to reduce offshore dependency and improve supply chain resilience.
Bias read (Center): The article presents a factual update on a corporate acquisition and expansion strategy without overt ideological framing. It focuses on operational details, financial figures, and technical specifications of the manufacturing platform, which aligns with a neutral, balanced reporting style. There is
